🇰🇷 Bay Ntn 33893 in South Korea

Bay Ntn 33893 (imidacloprid) regulatory status in South Korea.

Marketing authorisation

MFDS

  • Status: likely_approved

Bay Ntn 33893 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Neuroscience approved in South Korea

Frequently asked questions

Is Bay Ntn 33893 approved in South Korea?

Yes. MFDS has authorised it.

Who is the marketing authorisation holder for Bay Ntn 33893 in South Korea?

Marketing authorisation holder not available in our data.